Evotec Agrees to Buy DeveloGen for $17.9M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said it has signed a definitive agreement to buy biopharmaceutical discovery and development firm DeveloGen for up to €14 million ($17.9 million).

As part of the deal, DeveloGen shareholders are also eligible for deferred payments based on milestones and royalty income.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.